Profile data is unavailable for this security.
About the company
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.
- Revenue in USD (TTM)0.00
- Net income in USD-51.47m
- Incorporated2013
- Employees63.00
- LocationPMV Pharmaceuticals IncOne Research WayPRINCETON 08540United StatesUSA
- Phone+1 (609) 642-6664
- Fax+1 (302) 636-5454
- Websitehttps://www.pmvpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PDS Biotechnology Corp | 0.00 | -40.56m | 76.95m | 25.00 | -- | 3.50 | -- | -- | -1.17 | -1.17 | 0.00 | 0.5975 | 0.00 | -- | -- | 0.00 | -73.98 | -51.63 | -98.74 | -59.00 | -- | -- | -- | -- | -- | -19.13 | 0.5286 | -- | -- | -- | -5.11 | -- | -- | -- |
| Allakos Inc | 0.00 | -178.75m | 78.32m | 131.00 | -- | 1.08 | -- | -- | -2.03 | -2.03 | 0.00 | 0.8142 | 0.00 | -- | -- | 0.00 | -87.64 | -42.71 | -97.01 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Agenus Inc | 160.43m | -227.86m | 78.35m | 389.00 | -- | -- | -- | 0.4884 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| CervoMed Inc | 10.07m | -11.95m | 79.24m | 8.00 | -- | 1.74 | -- | 7.87 | -1.60 | -1.60 | 1.35 | 5.53 | 0.3305 | -- | -- | 1,258,319.00 | -39.22 | -53.67 | -43.28 | -58.89 | -- | -- | -118.68 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Chimerix Inc | 159.00k | -83.59m | 80.94m | 72.00 | -- | 0.5961 | -- | 509.07 | -0.9351 | -0.9351 | 0.0018 | 1.51 | 0.0008 | -- | 1.92 | 2,208.33 | -43.54 | -30.45 | -48.29 | -34.09 | 2.52 | -- | -52,574.84 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| ESSA Pharma Inc | 0.00 | -27.67m | 81.23m | 50.00 | -- | 0.6301 | -- | -- | -0.6257 | -0.6257 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -19.33 | -23.01 | -19.81 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Armata Pharmaceuticals Inc | 5.47m | -41.36m | 81.41m | 66.00 | -- | -- | -- | 14.89 | -1.24 | -1.24 | 0.1312 | -1.41 | 0.0518 | -- | 1.02 | 82,833.34 | -39.21 | -59.78 | -116.66 | -72.70 | -- | -- | -756.59 | -1,113.72 | -- | -- | 1.90 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Clearside Biomedical Inc | 7.70m | -31.88m | 81.91m | 30.00 | -- | -- | -- | 10.63 | -0.4503 | -0.4503 | 0.1094 | -0.4654 | 0.2423 | -- | 9.23 | 256,766.70 | -100.27 | -63.57 | -122.24 | -81.77 | 97.01 | -- | -413.83 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
| Renovaro Inc | 0.00 | -115.69m | 82.37m | 25.00 | -- | 0.834 | -- | -- | -0.9343 | -0.9343 | 0.00 | 0.6223 | 0.00 | -- | -- | 0.00 | -128.97 | -39.86 | -158.19 | -42.11 | -- | -- | -- | -- | -- | -9.65 | 0.0259 | -- | -- | -- | -103.23 | -- | -37.12 | -- |
| PMV Pharmaceuticals Inc | 0.00 | -51.47m | 83.31m | 63.00 | -- | 0.421 | -- | -- | -0.9998 | -0.9998 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -21.24 | -21.16 | -22.36 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Invivyd Inc | 11.56m | -225.14m | 83.78m | 94.00 | -- | 1.01 | -- | 7.24 | -1.95 | -1.95 | 0.0996 | 0.6953 | 0.0529 | -- | 2.48 | 123,021.30 | -103.08 | -- | -135.83 | -- | 92.27 | -- | -1,946.87 | -- | 1.58 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -86.49m | 84.49m | 20.00 | -- | 1.77 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| Werewolf Therapeutics Inc | 3.39m | -62.12m | 84.67m | 45.00 | -- | 0.9294 | -- | 25.01 | -1.50 | -1.50 | 0.0819 | 2.04 | 0.0214 | -- | 1.06 | 72,042.55 | -39.26 | -- | -42.91 | -- | -- | -- | -1,834.55 | -- | -- | -- | 0.2228 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 84.82m | 32.00 | -- | 1.89 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Genelux Corp | 8.00k | -27.66m | 88.07m | 23.00 | -- | 2.63 | -- | 11,008.18 | -0.9537 | -0.9537 | 0.0003 | 0.9703 | 0.0002 | -- | -- | 347.83 | -74.41 | -- | -92.15 | -- | -- | -- | -345,750.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to PMV Pharmaceuticals Inc's reporting currency: US Dollar USD
42.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ArrowMark Colorado Holdings LLCas of 30 Sep 2024 | 3.65m | 7.08% |
| Sio Capital Management LLCas of 30 Sep 2024 | 3.21m | 6.24% |
| Euclidean Capital LLCas of 30 Sep 2024 | 2.63m | 5.10% |
| Alkeon Capital Management LLCas of 30 Sep 2024 | 2.34m | 4.55% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.27m | 4.41% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 2.08m | 4.04% |
| PFM Health Sciences LPas of 30 Sep 2024 | 2.01m | 3.90% |
| BML Capital Management LLCas of 30 Sep 2024 | 1.69m | 3.28% |
| Silverbay Capital Management LLCas of 30 Jun 2024 | 1.15m | 2.23% |
| D. E. Shaw & Co. LPas of 30 Sep 2024 | 1.04m | 2.02% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
